Bharat Biotech to donate 2 lakh doses of covaxin to Vietnam
3 years ago

Bharat Biotech to donate 2 lakh doses of covaxin to Vietnam

Live Mint  

Bharat Biotech will donate 2,00,000 doses of covaxin to The Republic of Vietnam, the Hyderabad based pharmaceutical company said on Thursday. This donation represents a gesture of goodwill to provide access to Bharat Biotech World Health Organization approved, indigenously developed covaxin to fight the covid-19 pandemic across borders, Suchitra Ella, Joint Managing Director of Bharat Biotech said. Bharat Biotech was invited by the Embassy of Vietnam for a one-on-one meeting with H.E the President of the National Assembly, to discuss avenues of cooperation, supplies, and technology transfer possibilities. “We believe in vaccine equity, global public health, and having access to the vaccine is vital for national health,” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech.

India National Bharat Biotech Biotech Covaxin Vietnam Bharat  national  doses  donate  biotech  lakh  vaccination  rate  covaxin  vietnam  bharat  health  republic  vaccine

History of this topic

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
4 months, 3 weeks ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister
4 months, 3 weeks ago

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister

New Indian Express  

NEW DELHI: Union health minister J P Nadda on Friday said that Bharat Biotech initially did not mention ICMR and NIV as co-inventors in the patent application for Covaxin and the application was corrected after objections were raised by the government. Covaxin, which was widely used as a Covid vaccine, was jointly developed by the Indian Council of Medical Research, …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR
6 months ago

Patent filings credit Bharat Biotech as ‘inventor’ of Covaxin, omit ICMR

The Hindu  

India’s first indigenously developed coronavirus vaccine, Covaxin, was a joint collaboration between the Indian Council of Medical Research and the Hyderabad-based Bharat Biotech International Limited with intellectual property rights jointly shared between the two organisations. The Minister’s statement said the ICMR would provide a “well characterised” virus strain for vaccine development, the BBIL would develop the final vaccine formulation and, …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India
1 year, 10 months ago

Bharat Biotech starts dispatching nasal vaccines: Why it’s a big thing for India

Live Mint  

The world's first intranasal heterologous booster dose has begun to be dispatched by Bharat Biotech to hospitals, Executive Chairman Dr. Krishna Ella announced on February 5. He discussed the delivery of vaccines under the bilateral agreement between the Ella Foundation and the UW-Madison Global Health Institute for the establishment of the first-ever UW-Madison One Health Center in India for improving …

Centre rolls out first nasal Covid vaccine as booster
1 year, 10 months ago

Centre rolls out first nasal Covid vaccine as booster

Hindustan Times  

India on Thursday rolled out the first nasal vaccine against Covid-19, to be administered as a primary or booster dose for adults, potentially widening the pool of people who may take a third vaccine against the infection, cutting tertiary costs, and easing pressures on supply and storage networks. “Being the world’s first intranasal Covid-19 vaccine, this marks a glorious tribute …

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26
1 year, 11 months ago

First Indian intranasal Covid vaccine by Bharat Biotech to be launched on Jan 26

India TV News  

Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella said here on Saturday. In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses
1 year, 11 months ago

Biological E, Bharat Biotech Together Sitting on Stockpile of 250 Million Covid Vaccine Doses

News 18  

Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of Covid-19 vaccines ready to dispatch as and when orders are received. According to respective company sources, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
1 year, 11 months ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
1 year, 11 months ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here
1 year, 11 months ago

Price of Bharat Biotech’s nasal Covid vaccine revealed. Details here

Live Mint  

Bharat Biotech's intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose for those aged 18 years and above according to reports will be available at ₹800+ GST+ hospital charges according to sources. The country’s first intranasal covid vaccine will be rolled out in the fourth week of January as a booster dose for those …

Nasal vaccines to roll out in private hospitals soon
2 years ago

Nasal vaccines to roll out in private hospitals soon

Hindustan Times  

A new coronavirus vaccine used as a nasal spray will only be available at private health facilities and the Co-WIN platform was set to be tweaked on Friday to allow people to immediately begin booking shots, people aware of the matter said on Friday. On Thursday, India’s technical expert committee on immunization— National Technical Advisory Group on Immunisation —recommended the …

Bharat Biotech’s nasal vaccine to be available as booster dose
2 years ago

Bharat Biotech’s nasal vaccine to be available as booster dose

The Hindu  

With the threat of COVID-19 resurfacing and India ramping up preventive health surveillance measures, Health Minister Mansukh Mandaviya said on Friday that a vaccine, which could be administered as nasal drops, would henceforth be available for public use. “We have made available a nasal vaccine, developed by Bharat Biotech, that can be used as a precaution dose. A spokesperson for …

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN
2 years ago

COVID-19: Centre approves Bharat Biotech's intranasal vaccine, to be available on CoWIN

Firstpost  

The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening New Delhi: Bharat Biotech’s intranasal COVID-19 vaccine has been approved by the Ministry of Health and Family Welfare for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take
2 years, 1 month ago

COVID: 50 million Covaxin doses set to expire early 2023 due to poor off take

India TV News  

Highlights Covaxin lying with the firm are set to expire early next year There are no takers owing to poor demand, said company sources India reported 1,082 fresh COVID-19 cases on Saturday Covaxin news: Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers …

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval
2 years, 3 months ago

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval

The Hindu  

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine has been approved by Central Drugs Standard Control Organisation for primary immunization against COVID-19 in 18+ age group for restricted use in emergencies, Health Minister Mansukh Mandaviya tweeted on Tuesday. Dr. Krishna Ella, chairman and managing director, Bharat Biotech, said: “iNCOVACC will be a global game changer in intra-nasal vaccines technology and delivery …

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech
2 years, 4 months ago

COVID-19 intranasal vaccine Phase III trials over, proven safe, says Bharat Biotech

Deccan Chronicle  

HYDERABAD: Bharat Biotech International Limited on Monday said its COVID-19 intranasal vaccine has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. Suchitra K Ella, Joint Managing Director, Bharat Biotech, …

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report
2 years, 4 months ago

Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report

Live Mint  

The government has approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin, news agency PTI has reported on 10 August citing official sources. "Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of …

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients
2 years, 4 months ago

In A First, Biological E's Corbevax Approved As Covid Booster for Covishield, Covaxin Recipients

News 18  

The Centre has approved Biological E’s Corbevax as a Covid-19 precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin. Union Health Secretary Rajesh Bhushan said, “Corbevax will be available as precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines …

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon
2 years, 4 months ago

Govt Nod for Corbevax as Booster for Adults Vaccinated with Covishield, Covaxin Soon

News 18  

The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday. “Corbevax will be considered as a precaution dose after completion of 6 months or 26 weeks from the date of administration of the second dose …

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership
2 years, 5 months ago

India's Covid Vaccinations Hit 200 Crore Mark in Big Milestone for 7-Phase Drive Under Modi's Leadership

News 18  

India has crossed record 200 crore mark in Covid-19 vaccinations within 18 months of launching the inoculation exercise in January last year. #200CroreVaccinations https://t.co/FtobFYBprV— Dr Mansukh Mandaviya July 17, 2022 A seven-phase vaccination drive was followed on the principle of Prioritization for Vaccine Administration based on scientific advice and global best practices, government officials told News18. While some experts had …

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years
2 years, 5 months ago

NTAGI Panel Recommends Use of Covid Vaccines Corbevax, Covaxin for Kids Aged 5-12 Years

News 18  

The NTAGI's Standing Technical Sub-Committee approved the use of COVID-19 vaccines Corbevax and Covaxin for children aged between five and 12 years, official sources said on Friday. Data of Biological E's Corbevax and Bharat Biotech's Covaxin for children aged between five and 12 years were reviewed in the STSC meeting held on June 16 and members decided that the vaccines …

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here
2 years, 5 months ago

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here

Live Mint  

Biological E's Corbevax and Bharat Biotech's Covaxin on July 8 received the nod from the National Technical Advisory Group on Immunisation's Standing Technical Sub-Committee for use among children aged between 5-12 years. The Drugs Controller General of India granted emergency use authorisation to the Biological E's Corbevax for 5-12 year old and Bharat Biotech's Covaxin for minors belonging to the …

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US
2 years, 5 months ago

Serum Institute gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

India Today  

The government has allowed Serum Institute of India to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer, official sources said on Friday. "It is a matter of pride for us and our country that, in …

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI
2 years, 5 months ago

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Hindu  

Allowing Biological E’s Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said. “The National Technical Advisory Group on Immunisation will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated …

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed
2 years, 6 months ago

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed

News 18  

Bharat Biotech on Saturday said that the clinical Phase III trials of the nasal vaccine for Covid-19 have been completed and that the company will submit its data with Drugs Controller General of India next month. Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said, if everything is okay, then they will get permission to launch …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
2 years, 6 months ago

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

Firstpost  

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity Hyderabad: Bharat Biotech International Limited on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. Bharat Biotech had conducted phase II/III, open-label, and multi-centre …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 6 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

Covaxin Gets DCGI Nod for Kids Aged 6-12 Yrs; Corbevax Cleared for 5-12 Yr Olds; 12+ to Get Zydus Jab
2 years, 7 months ago

Covaxin Gets DCGI Nod for Kids Aged 6-12 Yrs; Corbevax Cleared for 5-12 Yr Olds; 12+ to Get Zydus Jab

News 18  

In a move that could mitigate the vulnerability of children to the SAR-COV-2 virus, the Drug Controller General of India gave a restricted emergency use authorisation to three vaccines — Bharat Biotech’s Covaxin, Biological E’s Corbevax and Zydus Cadila’s ZyCov-D — for various age groups of children. Last week, the expert panel of India’s apex drug regulator recommended grant of …

India Could Start Vaccinating Younger Kids Soon as Govt Panel Suggests Covaxin for 6-12 Age Group​ - News18
2 years, 8 months ago

India Could Start Vaccinating Younger Kids Soon as Govt Panel Suggests Covaxin for 6-12 Age Group​ - News18

News 18  

Amid a resurgence of Covid-19 cases, especially among children, the focus is back on vaccinating kids and now, there are indications from the government that India could soon start coronavirus jabs for younger children. Covaxin in the 6-12 age group The Subject Expert Committee has recommended Bharat Biotech’s Covaxin to the Drug Controller General of India for children aged between …

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds
2 years, 8 months ago

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

Deccan Chronicle  

New Delhi: The Subject Expert Committee of the Drug Controller General of India has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said. This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. However, the …

Govt panel approves use of Corbevax for 5-12 year age group
2 years, 8 months ago

Govt panel approves use of Corbevax for 5-12 year age group

India Today  

Expert panel of Drug Controller General of India -- India’s drug regulator-- has recommended granting emergency use authorisation for Biological E's Covid-19 vaccine Corbevax for children in 5 to 12 years age group. "The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E's EUA application has recommended granting emergency use authorisation for use of Corbevax in …

Thailand Gets India-made Covid Vaccine Covovax Under Quad Initiative
2 years, 8 months ago

Thailand Gets India-made Covid Vaccine Covovax Under Quad Initiative

News 18  

Thailand on Thursday received 200,000 doses of India-made Covovax vaccines as part of a flagship initiative of the Quad grouping to help countries combat the coronavirus pandemic. The vaccine doses were handed over to Thai Deputy Prime Minister Anutin Charnvirakul in Bangkok by India’s Ambassador to Thailand Suchitra Durai, Australian envoy Allan McKinnon, Japan’s Nashida Kazuya and US Charge d’Affaires …

Weighing the choices: on precautionary vaccine doses
2 years, 8 months ago

Weighing the choices: on precautionary vaccine doses

The Hindu  

As India sees a steady slump in its daily coronavirus count, the Centre has announced opening up the third, or ‘precautionary doses’, to everyone over 18 years. A major aspect of vaccines is the risk of adverse events following vaccination, and previous experience has suggested that certain vaccines may induce a higher risk of blood clots in younger populations. With …

How govt spent Rs 35,000 crore on procuring Covid-19 vaccines | RTI Exclusive
2 years, 8 months ago

How govt spent Rs 35,000 crore on procuring Covid-19 vaccines | RTI Exclusive

India Today  

The Ministry of Health announced last week that the precautionary third dose of Covid-19 vaccine would be available for the age group of 18-59 years on payment at private centres from April 10. In response to our query dated February 4, 2022, the Department of Health and Family Welfare said, "As per the announcement in Parliament during Budget session 2021, …

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference
2 years, 8 months ago

Serum Institute to Give Free Covishield Vials to Private Vaccination Centres to Compensate for Price Difference

News 18  

A day after slashing the price of the precaution dose of Covishield to Rs 225 per shot for private hospitals, the Serum Institute of India told the Centre on Sunday that it will compensate for the price difference for the unexpired stocks lying with private centres in the form of free vials of fresh stocks, official sources said. Vaccine majors …

Covishield, Covaxin to now cost private hospitals Rs 225 per dose
2 years, 8 months ago

Covishield, Covaxin to now cost private hospitals Rs 225 per dose

India Today  

A single dose of the Serum Institute of India's Covishield and Bharat Biotech's Covaxin will now cost private hospitals Rs 225. Adar Poonawalla, CEO of SII, said in a tweet on Saturday that the vaccine maker has decided to slash the prices of the Covid-19 jab for private hospitals from Rs 600 to Rs 225 after consultation with the central …

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production
2 years, 8 months ago

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production

India Today  

In a setback to India’s indigenous vaccine against Covid-19, the World Health Organisation has issued a statement saying that the body is suspending the supply of Bharat Biotech’s Covaxin through UN agencies. A day earlier, Bharat Biotech issued a statement saying the company “announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply …

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies
2 years, 8 months ago

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies

India TV News  

Highlights The WHO has suspended the supply of Covaxin vaccine under the United Nations procurement The development comes after an inspection of the COVID-19 vaccine last month Earlier too, Bharat Biotech had said it is working on further improvements and upgrades Bharat Biotech has said it is working on upgrades to ensure that the production of Covaxin continues to meet …

WHO pauses Covaxin supply via UN bodies
2 years, 8 months ago

WHO pauses Covaxin supply via UN bodies

The Hindu  

Bharat Biotech to upgrade facility The World Health Organisation on Saturday suspended supply of Bharat Biotech’s COVID vaccine, Covaxin, to allow the manufacturer to upgrade facilities and address deficiencies found during an inspection last month. ‘Will meet standards’ In a statement issued on April 1, Bharat Biotech said it was fully committed to implementing facility improvements and upgrades to ensure …

WHO suspends Covaxin supply to UN agencies
2 years, 8 months ago

WHO suspends Covaxin supply to UN agencies

Deccan Chronicle  

Hyderabad: The World Health Organization has confirmed it has suspended the supply of Covaxin, produced by city-based Bharat Biotech, through UN procurement agencies and recommending to countries that received the covid vaccine to take actions as appropriate. A statement issued by WHO on Saturday said the suspension is in response to the outcomes of its post EUL inspection held between …

Discover Related